KOPRAN The co. has set up a new API plant at Panoli, commercial production at this facility is expected to be started from Q3 FY25. In FY23, it completed upgradation and expansion of the multi-product plant at the Mahad facility for existing products and to manufacture new molecules.
An integrated Pharmaceutical Company, committed to supplying International
Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally.
State-of-the-art manufacturing facilities and products with various accreditations
and approvals by major global regulatory authorities.
The formulations vertical is operated through Kopran Limited.
The API vertical is being operated under Kopran Research Laboratories Ltd.
(KRLL), a wholly owned subsidiary of Kopran Limited
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。